Board member Monica Bertagnolli exits Natera (NASDAQ: NTRA)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Natera, Inc. reported that Monica Bertagnolli has resigned from its Board of Directors and all board committees, effective July 1, 2026. She is leaving due to her new position with the National Academy of Medicine. The company states her resignation is not related to any disagreement over operations, policies, or practices.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Board of Directors, Emerging growth company, Section 12(b), Nasdaq Global Select Market
4 terms
Board of Directors financial
"notified the Board of Directors (the “Board”) of Natera, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
Nasdaq Global Select Market financial
"NTRA | Nasdaq Stock Market LLC ( Nasdaq Global Select Market)"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
FAQ
What did Natera (NTRA) disclose in this 8-K filing?
Natera disclosed that board member Monica Bertagnolli resigned from its Board of Directors and all board committees, effective July 1, 2026. The company explained the departure relates to her new role at the National Academy of Medicine, not to any dispute over company matters.
Who resigned from Natera (NTRA)’s Board of Directors?
Monica Bertagnolli resigned from Natera’s Board of Directors and any committees on which she served. The filing notes that her decision was connected to accepting a position with the National Academy of Medicine, and not due to disagreements regarding Natera’s operations, policies, or practices.
When did Monica Bertagnolli’s resignation from Natera’s board become effective?
Her resignation became effective on July 1, 2026. The same date is cited both for notifying the Board and for the effectiveness of her departure, indicating an immediate transition from her governance and committee responsibilities at Natera on that day.
Why did Monica Bertagnolli resign from Natera (NTRA)’s board?
She resigned due to her new position with the National Academy of Medicine. The company explicitly states that her departure was not the result of any disagreement with Natera regarding its operations, policies, or practices, suggesting a career-driven, rather than conflict-driven, change.
Did Natera report any disagreements linked to this board resignation?
No. Natera states that Monica Bertagnolli’s resignation was not due to any disagreement with the company on operations, policies, or practices. This language is commonly used to reassure investors that a director’s departure does not stem from internal disputes or governance conflicts.
Does the filing mention changes to Natera’s executive officers?
The filing does not describe changes to executive officers; it focuses on a board-level resignation. It confirms that Chief Financial Officer Michael Brophy signed the report as principal financial and accounting officer, but no alterations to his role are indicated within this disclosure.